Genetic Variants in the ADIPOQ Gene and the Risk of Metabolic Syndrome: A Case‐Control Study of a Chinese Han Population

Juan Du,Xin Hua Ye,Qian Li,Xiaofang Yu,Jinluo Cheng,Jianhua Ma,Yanqin Gao,Ying Lu,Wencong Du,Hui Shi,Xu Zhao,Qing Ye,Ling Zhou
DOI: https://doi.org/10.1111/j.1469-1809.2012.00699.x
2012-01-01
Annals of Human Genetics
Abstract:Our aim was to investigate whether the ADIPOQ gene polymorphisms are associated with the metabolic syndrome (MetS). Genotypes of MetS patients (n= 1049) and normal controls (n= 1092) were analysed by TaqMan® assay, and serum adiponectin concentration was measured by ELISA. The variant genotypes rs266729CG; rs1063539GC, GC/CC; rs16861205AA and rs7649121AT, AT/TT (Adjusted P= 0.037, 0.044, 0.025, 0.011, 0.019, 0.020, respectively) of the ADIPOQ gene were associated with MetS. Patients with rs266729CG, CG/GG genotypes (P= 0.034, 0.035) and rs7649121AT, AT/TT genotypes (P= 0.013, 0.022) had higher levels of serum adiponectin than those with the CC and AA genotypes respectively. Furthermore, the prevalence of haplotypes GGAAAATC and GGGTAACC was lower in cases (10.7% and 4.5%) than in controls (12.1% and 5.9%) [Adjusted ORs (95% CIs) = 0.70 (0.54–0.91), 0.65 (0.46–0.92)]. The ADIPOQ gene variants associated with the risk of MetS in this study must be validated by further functional studies to reveal any potential effects on metabolism.
What problem does this paper attempt to address?